“AN ANTI-PROSTATE CANCER PEPTIDE”

Abstract

ABSTRACT The present invention discloses a novel peptide with anti-prostate cancer activity having amino acid sequence selected from the group consisting of SEQ ID No.01 5 in which TIP60- NRB peptide interacts with NTD region of AR or Androgen receptor thereby AR protein is destabilized. SEQ ID NO – 1.

Specification

Description:AN ANTI-PROSTATE CANCER PEPTIDE
FIELD OF THE INVENTION
The present invention generally relates to medical sciences. Specifically, the present invention relates to field of cancer biology. More specifically, the present invention relates to healing of prostate cancer. Particularly, the present invention 5 relates to peptide-based therapeutic agent to inhibit the growth and proliferation of prostate cancer cells. More particularly, the present invention relates to an anti-prostate cancer peptide for inhibiting prostate carcinoma cells.
BACKGROUND OF THE INVENTION In recent years, prostate cancer is one of the most common cancers affecting men 10 worldwide. It originates in the prostate gland, a small walnut-shaped gland located below the bladder and in front of the rectum. The primary function of the prostate is to produce seminal fluid, which nourishes and transports sperm. Most prostate tumors remain small and cause no health problems. These are managed with active surveillance, monitoring the tumor with regu , C , C , Claims:WE CLAIM:
1.
An anti-prostate cancer peptide, comprising:
amino acid sequence in SEQ ID No.01,
wherein TIP60- NRB peptide interacts with NTD region of AR or Androgen receptor thereby AR protein is destabilized. 5
2.
The anti-prostate cancer peptide as claimed in claim 1, wherein the amino acid sequence is Gln-Ala-Tyr-Ile-Leu-Thr-Leu-Ser-Glu-Asp-Ile-Val-Asp-Gly-His-Glu-Arg-Ala-Met-Leu-Lys-Arg-Leu-Leu-Arg-Ile-Asp-Ser-Lys-Cys-Leu-His-Phe-Thr-Pro-Lys-Asp-Trp-Ser-Lys-Arg-Gly-Lys-Trp.
10
3.
The anti-prostate cancer peptide as claimed in claim 2, wherein the peptide constructed in form of a full-length 3D structure of the AR protein, wherein the AR protein comprises a N-terminal domain (NTD), a DNA binding domain (DBD), a hinge region, and a ligand binding domain (LBD) at the C-terminal, using a RoseTTA fold deep learning-based method provided by 15 the Robetta server, thereby the structure of the TIP60-NRB peptide is obtained.
4.
The anti-prostate cancer peptide as claimed in claim 3, wherein the peptide is generat

Documents